Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats.
The effect of repeated administration of imipramine or mirtazapine, two antidepressant drugs with different mechanisms of action, was studied on the stress-induced increase in the extracellular concentration of norepinephrine in the prefrontal cortex of freely moving rats. Exposure to footshock in control rats induced a marked increase in extracellular norepinephrine concentrations in the prefrontal cortex (+120%). Long-term administration with imipramine or mirtazapine (10 mg/kg, i.p., twice or once a day, respectively, for 14 days) reduced (+50%) the effect of stress on basal norepinephrine output. Acute administration of FG7142 (30 mg/kg, i.p.), an anxiogenic benzodiazepine receptor inverse agonist, induced a marked increase in norepinephrine output (+90%) in control rats. In rats chronically treated with imipramine or mirtazapine this effect was completely antagonized. On the contrary, acute administration of these antidepressant drugs failed to reduce stress- and FG7142-induced increase in norepinephrine output. The plastic changes in the sensitivity of norepinephrine neurons to footshock stress and drug-induced anxiogenic stimuli may reveal a new important neuronal mechanism involved in the long-term modulation of emotional state. This action might be relevant for the anxiolytic and antidepressant effect of antidepressant drugs.
Dazzi
Laura
L
Department of Experimental Biology "B. Loddo," Chair of Pharmacology, University of Cagliari, Cagliari, Italy. dazzi@vaxca1.unica.it
Ladu
Stefania
S
Spiga
Francesca
F
Vacca
Giada
G
Rivano
Antonella
A
Pira
Luigi
L
Biggio
Giovanni
G
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D001007:Anxiety / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D002243:Carbolines / Q000494:pharmacology; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism; D003863:Depression / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004558:Electric Stimulation; D018756:GABA Antagonists / Q000494:pharmacology; D007099:Imipramine / Q000494:pharmacology*; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000078785:Mirtazapine; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism; D013312:Stress, Physiological / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D002243:Carbolines; D018756:GABA Antagonists; D011963:Receptors, GABA-A; D008803:Mianserin; C035874:FG 7142; D000078785:Mirtazapine; D007099:Imipramine; D009638:Norepinephrine